Driven by the central role of NF-κB signaling and MYD88 in MZL, we studied the pharmacological inhibition of IRAK4 with emavusertib in two MZL cell lines and their derivatives with acquired resistance to FDA approved PI3K and BTK inhibitors. The gene discussed is MYD88; the disease is marginal zone lymphoma.